← ANALYST RATINGS · TIPRANKS
Lexeo Therapeutics, Inc. (LXEO): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $18.00, the highest $20.00, the lowest $15.00. The average is +581.8% from the last price of $2.64.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $3.00+20.0% | Hold | +13.6% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $3.00+20.0% | Hold | +13.6% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $2.50−16.7% | Hold | −5.3% | Reiterated | 15.10.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $2.50−16.7% | Hold | −5.3% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.00 → $2.50−16.7% | Hold | −5.3% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $2.50−16.7% | Sell | −5.3% | Downgrade | 14.10.26on TipRanks 11:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $2.50−16.7% | Hold | −5.3% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $2.50−16.7% | Hold | −5.3% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | +13.6% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | +13.6% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | +13.6% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Sell | +13.6% | Downgrade | 13.10.26on TipRanks 06:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Hold | +13.6% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | +13.6% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $17.00 | Buy | +543.9% | Reiterated | 05.10.26on TipRanks 06:55 | −4.1%next day −3.8% · 5 days −11.3% | ↗ |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 | Sell | +32.6% | Downgrade | 02.10.26on TipRanks 11:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 | Hold | +32.6% | Reiterated | 30.09.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 | Hold | +32.6% | Reiterated | 30.09.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 | Hold | +32.6% | Reiterated | 30.09.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 | Hold | +32.6% | Reiterated | 30.09.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 | Hold | +32.6% | Reiterated | 30.09.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 | Hold | +32.6% | Reiterated | 30.09.26on TipRanks 12:05 | — | |
| Unknown Analyst | Leerink Partners | $15.00 | Buy | +468.2% | Reiterated | 23.09.26on TipRanks Sep 24 04:05 | −12.8%next day −3.6% · 5 days −3.3% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $20.00 | Buy | +657.6% | Reiterated | 23.09.26on TipRanks 09:10 | −12.8%next day −3.6% · 5 days −3.3% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $20.00 | Buy | +657.6% | Reiterated | 12.08.26on TipRanks Aug 13 07:45 | +1.6%next day +1.2% · 5 days +10.7% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $17.00 | Buy | +543.9% | Reiterated | 06.07.26on TipRanks 01:55 | −2.8%next day +4.6% · 5 days +1.3% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $12.00 → $9.00−25.0% | Buy | +240.9% | Reiterated | 25.06.26on TipRanks 07:41 | −4.0%next day +1.8% · 5 days −1.6% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $17.00 | Buy | +543.9% | Reiterated | 11.05.26on TipRanks 13:50 | +4.7%next day −6.7% · 5 days −23.0% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $19.00 | Buy | +619.7% | Reiterated | 30.03.26on TipRanks Mar 31 07:15 | −3.1%next day +6.0% · 5 days +15.4% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $13.00 → $10.00−23.1% | Buy | +278.8% | Reiterated | 13.01.26on TipRanks 10:52 | −8.3%next day +4.4% · 5 days −1.5% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | $10.54 → $25.00+137.2% | Buy | +847.0% | Reiterated | 13.01.26on TipRanks 10:52 | −8.3%next day +4.4% · 5 days −1.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Lexeo Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $18.00 at a price of $3.38 (+432.5%); now: $18.00 at $2.64 (+581.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 5 | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 14.12.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.32 (from $-0.35 to $-0.25). Last quarter: $-0.30.
Best top-analyst consensus in the sector · Healthcare
About Lexeo Therapeutics, Inc.
- CEO: R. Nolan Townsend
- Employees: 63
- 345 Park Avenue South, New York City, NY, 10010, US
- www.lexeotx.com
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Data from the stock’s TipRanks forecast page, read 117 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗